319 related articles for article (PubMed ID: 21179455)
1. The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis.
Panneton WM; Kumar VB; Gan Q; Burke WJ; Galvin JE
PLoS One; 2010 Dec; 5(12):e15251. PubMed ID: 21179455
[TBL] [Abstract][Full Text] [Related]
2. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis.
Burke WJ; Li SW; Williams EA; Nonneman R; Zahm DS
Brain Res; 2003 Nov; 989(2):205-13. PubMed ID: 14556942
[TBL] [Abstract][Full Text] [Related]
3. Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
Follmer C; Coelho-Cerqueira E; Yatabe-Franco DY; Araujo GD; Pinheiro AS; Domont GB; Eliezer D
J Biol Chem; 2015 Nov; 290(46):27660-79. PubMed ID: 26381411
[TBL] [Abstract][Full Text] [Related]
4. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat.
McCormack AL; Thiruchelvam M; Manning-Bog AB; Thiffault C; Langston JW; Cory-Slechta DA; Di Monte DA
Neurobiol Dis; 2002 Jul; 10(2):119-27. PubMed ID: 12127150
[TBL] [Abstract][Full Text] [Related]
5. 3,4-dihydroxyphenylacetaldehyde: a potential target for neuroprotective therapy in Parkinson's disease.
Burke WJ
Curr Drug Targets CNS Neurol Disord; 2003 Apr; 2(2):143-8. PubMed ID: 12769806
[TBL] [Abstract][Full Text] [Related]
6. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine.
Burke WJ; Kumar VB; Pandey N; Panneton WM; Gan Q; Franko MW; O'Dell M; Li SW; Pan Y; Chung HD; Galvin JE
Acta Neuropathol; 2008 Feb; 115(2):193-203. PubMed ID: 17965867
[TBL] [Abstract][Full Text] [Related]
7. Effects of a unilateral stereotaxic injection of Tinuvin 123 into the substantia nigra on the nigrostriatal dopaminergic pathway in the rat.
Jackson-Lewis V; Liberatore G
Brain Res; 2000 Jun; 866(1-2):197-210. PubMed ID: 10825495
[TBL] [Abstract][Full Text] [Related]
8. Transneuronal degeneration in substantia nigra pars reticulata following striatal excitotoxic injury in adult rat: time-course, distribution, and morphology of cell death.
Stefanis L; Burke RE
Neuroscience; 1996 Oct; 74(4):997-1008. PubMed ID: 8895868
[TBL] [Abstract][Full Text] [Related]
9. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
10. Morphological and biochemical adaptations to unilateral dopamine denervation of the neostriatum in newborn rats.
Penit-Soria J; Durand C; Herve D; Besson MJ
Neuroscience; 1997 Apr; 77(3):753-66. PubMed ID: 9070750
[TBL] [Abstract][Full Text] [Related]
11. Dopamine cell morphology and glial cell hypertrophy and process branching in the nigrostriatal system after striatal 6-OHDA analyzed by specific sterological tools.
Gomide V; Bibancos T; Chadi G
Int J Neurosci; 2005 Apr; 115(4):557-82. PubMed ID: 15804725
[TBL] [Abstract][Full Text] [Related]
12. Striatal infarction in the rat causes a transient reduction of tyrosine hydroxylase immunoreactivity in the ipsilateral substantia nigra.
Soriano MA; Justicia C; Ferrer I; Rodríguez-Farré E; Planas AM
Neurobiol Dis; 1997; 4(5):376-85. PubMed ID: 9440126
[TBL] [Abstract][Full Text] [Related]
13. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic, neurochemical, stereological and neuropathological studies on the potential effects of paraquat in the substantia nigra pars compacta and striatum of male C57BL/6J mice.
Breckenridge CB; Sturgess NC; Butt M; Wolf JC; Zadory D; Beck M; Mathews JM; Tisdel MO; Minnema D; Travis KZ; Cook AR; Botham PA; Smith LL
Neurotoxicology; 2013 Jul; 37():1-14. PubMed ID: 23523781
[TBL] [Abstract][Full Text] [Related]
15. Decreased vesicular storage and aldehyde dehydrogenase activity in multiple system atrophy.
Goldstein DS; Sullivan P; Holmes C; Kopin IJ; Sharabi Y; Mash DC
Parkinsonism Relat Disord; 2015 Jun; 21(6):567-72. PubMed ID: 25829070
[TBL] [Abstract][Full Text] [Related]
16. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
17. Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers.
Killinger BA; Moszczynska A
J Neurochem; 2016 Feb; 136(3):510-25. PubMed ID: 26465779
[TBL] [Abstract][Full Text] [Related]
18. Kainic acid lesion-induced nigral neuronal death.
Foster JA; Bezin L; Groc L; Christopherson PL; Levine RA
J Chem Neuroanat; 2003 Aug; 26(1):65-73. PubMed ID: 12954531
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat.
Connor B; Kozlowski DA; Schallert T; Tillerson JL; Davidson BL; Bohn MC
Gene Ther; 1999 Dec; 6(12):1936-51. PubMed ID: 10637445
[TBL] [Abstract][Full Text] [Related]
20. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
